Cancer Research and Treatment

Original Articles

Pediatric cancer

Gonadal Function in Female Adolescent and Young Adult Survivors of Childhood Cancer: Hye Young Jin, Jun Ah Lee, Meerim Park, Hyeon Jin Park; Cancer Res Treat. 2023;55(3):992-1000. Published online January 31, 2023; DOI: https://doi.org/10.4143/crt.2022.1518

Purpose
Childhood cancer survivors (CCSs) are at risk for premature ovarian insufficiency (POI). The aim of this study is to evaluate ovarian function and associated health outcomes in female adolescent and young adult survivors of childhood cancer.
Materials and Methods
Sixty-nine female CCSs were enrolled. Medical records of CCSs were retrospectively reviewed. The subjects were categorized into three groups according to follicular stimulating hormone (FSH) levels (cutoff, 12, 40 IU/L). Anti-müllerian hormone (AMH) level less than 1 ng/mL was considered low AMH level.
Results
Of 69 subjects, 14 (20.3%) had POI and 14 (20.3%) had FSH levels between 12 and 40 IU/L. Forty-one of 69 (59.4%) had normal FSH levels. Pelvic irradiation and stem cell transplantation (SCT) were more frequently performed in subjects with POI (p=0.001 and p < 0.001). AMH levels were remarkably low when FSH levels were over 12 IU/L (p < 0.001). In multivariate analysis, cyclophosphamide equivalent dose and SCT were significant treatment factors for developing low AMH levels (p=0.005 and p=0.002, respectively). Total, low-density lipoprotein cholesterol and triglyceride were significantly different in three groups according to FSH levels (p=0.047, p=0.030, and p=0.045). Z-score of femur neck bone mineral density was significantly reduced when FSH levels were increased (p=0.011).
Conclusion
Gonadal dysfunction is common in CCSs. Gonadal function was associated with a few treatment factors known to increase the risk of POI. Regular monitoring of gonadal function is needed for better health outcomes.

Citations

Citations to this article as recorded by

Systematic Review of the Gonadotoxicity and Risk of Infertility of Soft Tissue Sarcoma Chemotherapies in Pre- and Postpubertal Females and Males
Marcel Steinmann, Anita Rietschin, Flavia Pagano, Tanya Karrer, Attila Kollár, Susanna Weidlinger, Michael von Wolff
Journal of Adolescent and Young Adult Oncology.2024;[Epub] CrossRef
Bone Mineral Density in Survivors of Childhood Cancer: A Meta-Analysis
Lilly Velentza, Panagiotis Filis, Mari Wilhelmsson, Per Kogner, Nikolas Herold, Lars Sävendahl
Pediatrics.2024;[Epub] CrossRef

3,160 View
160 Download
2 Web of Science
2 Crossref

Sarcoma

Incidence Patterns and Outcomes of Ewing Sarcoma in South Korea (1999-2017): A Retrospective Analysis Using Korea Central Cancer Registry Data: Jun Ah Lee, Jiwon Lim, Dayeon Park, Hye Young Jin, Meerim Park, Hyeon Jin Park, Jong Woong Park, June Hyuk Kim, Hyun Guy Kang, Young-Joo Won; Cancer Res Treat. 2022;54(2):590-596. Published online July 20, 2021; DOI: https://doi.org/10.4143/crt.2021.311

Abstract PDF PubReader ePub

Purpose
Due to low incidence, epidemiologic data of Ewing sarcoma in the Asian population are scarce. We aimed to examine the incidence pattern and outcome of patients with Ewing sarcoma in the Republic of Korea.
Materials and Methods
Data of patients with Ewing sarcoma diagnosed between 1999 and 2017 were obtained from the Korea Central Cancer Registry (KCCR). Incidence, clinical characteristics, and survival rates were analyzed and compared between different age groups.
Results
There were 788 cases (459 males, 329 females), with a median age at diagnosis of 20 years. The age-standardized rate of Ewing sarcoma was 1.01. The number of cases and incidence rates in each age group were as follows: children, 1.6; adolescents and young adults (AYA), 0.93; adults, 0.44; and elderly, 0.53. There were more male cases in children and the AYA group (p < 0.001). Extraskeletal tumors (p < 0.001), primary sites other than extremity (p=0.007), and presence of metastasis at diagnosis (p=0.031) were more frequent in the adults and elderly group. With a median survival time of 78 months, the 5-year overall survival (OS) rate of the entire cohort was 52%. Children fared best (5-year OS, 75%), and the 5-year OS of AYA patients (51%) approximated the OS of the entire cohort. A two-fold difference of 5-year OS was observed between adults and elderly patients (42% vs. 19%). On univariate and multivariate analyses, age ≥ 15 years and presence of metastasis were adverse prognostic factors.
Conclusion
This was the first epidemiologic study of Ewing sarcoma using the KCCR data. With a similar incidence to other Asian countries, the survival rate was slightly lower than that of Euro-American cases. Collaborative clinical studies are necessary to improve the outcome of Ewing sarcoma in low-incidence populations.

Citations

Citations to this article as recorded by

Twenty‐year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors
Yao Xu, Fanqi Shi, Yanting Zhang, Mengfan Yin, Xiuxin Han, Jinyan Feng, Guowen Wang
International Journal of Cancer.2024; 154(2): 226. CrossRef
A Machine Learning-Based Predictive Model for Predicting Lymph Node Metastasis in Patients With Ewing’s Sarcoma
Wenle Li, Qian Zhou, Wencai Liu, Chan Xu, Zhi-Ri Tang, Shengtao Dong, Haosheng Wang, Wanying Li, Kai Zhang, Rong Li, Wenshi Zhang, Zhaohui Hu, Su Shibin, Qiang Liu, Sirui Kuang, Chengliang Yin
Frontiers in Medicine.2022;[Epub] CrossRef
TrkC, a novel prognostic marker, induces and maintains cell survival and metastatic dissemination of Ewing sarcoma by inhibiting EWSR1-FLI1 degradation
Min Soo Kim, Won Sung Lee, Hanki Lee, Wook Jin
Cell Death & Disease.2022;[Epub] CrossRef

5,876 View
120 Download
2 Web of Science
3 Crossref

Case Report

Hyperammonemic Encephalopathy Mimicking Ornithine Transcarbamylase Deficiency in Fibrolamellar Hepatocellular Carcinoma: Successful Treatment with Continuous Venovenous Hemofiltration and Ammonia Scavengers: Jeong-Seon Lee, Hye Young Jin, Jung Min Ko, Seoung Hoon Kim, Nayoung Han, Byung Kiu Park, Meerim Park, Hyeon Jin Park, Jun Ah Lee; Cancer Res Treat. 2021;53(1):283-288. Published online September 7, 2020; DOI: https://doi.org/10.4143/crt.2020.575

Abstract PDF PubReader ePub

Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare liver cancer affecting adolescents and young adults without any pre existing liver disease. Hyperammonemic encephalopathy (HAE) is a serious paraneoplastic syndrome, and several cases of HAE have been reported in patients with FLHCC. This condition is rare; hence, there are currently no management guidelines for cancer-related HAE. Herein, we report a case of an 18-year-old man with advanced FLHCC who developed HAE during the first course of chemotherapy consisting of cisplatin, doxorubicin, 5-fluorouracil, and interferon-α. He was successfully treated with continuous venovenous hemofiltration, sodium benzoate, sodium phenylbutyrate, and amino acid supplementation for HAE. After the second course of chemotherapy, he underwent surgery, and thereafter, his ammonia levels were normal without any ammonia scavenger therapy. Treatments for HAE described here will be helpful for this rare, but serious metabolic complication of FLHCC and could partially applied to HAE related to any malignancies.

Citations

Citations to this article as recorded by

Mitochondrial targets in hyperammonemia: Addressing urea cycle function to improve drug therapies
Marco F. Moedas, Ricardo J.M. Simões, Margarida F.B. Silva
Biochemical Pharmacology.2024; 222: 116034. CrossRef
Fibroadenoma Intracanalicular Hipercelular: uma revisão de literatura e relato de 5 casos
Isadora Benevides Silva Gondim Nascimento, Roberta Pereira Guerra Pedra, Amanda Veloso Teixeira, Maria Isabel Teles Nogueira, Kaio Henrique Oliveira Pontes
Journal Archives of Health.2024; 5(3): e1860. CrossRef
Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma
Solomon N. Levin, Michael D. Tomasini, James Knox, Mahsa Shirani, Bassem Shebl, David Requena, Jackson Clark, Søren Heissel, Hanan Alwaseem, Rodrigo Surjan, Ron Lahasky, Henrik Molina, Michael S. Torbenson, Barbara Lyons, Rachael D. Migler, Philip Coffino
Science Advances.2023;[Epub] CrossRef
WITHDRAWN: Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review
Arwa Ahmed, Fateen Ata, Mohammed Gaber, Mahir Petkar, Ahmed Mahfouz, Peter Schirmacher, Sara Musa, Ahmed Hashim
Current Problems in Cancer: Case Reports.2022; : 100141. CrossRef
Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review
Arwa Ahmed, Fateen Ata, Mohammed Gaber, Mahir Petkar, Ahmed Mahfouz, Peter Schirmacher, Sara Musa, Ahmed Hashim
Current Problems in Cancer.2022; 46(3): 100847. CrossRef
Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias
Teodoro Jerves, Nenad Blau, Carlos R. Ferreira
Molecular Genetics and Metabolism.2022; 136(2): 118. CrossRef
Paraneoplastic syndromes in hepatocellular carcinoma: a review
Yuki Ong, Cheong Wei Terence Huey, Vishalkumar Girishchandra Shelat
Expert Review of Gastroenterology & Hepatology.2022; 16(5): 449. CrossRef
Collagen Remodeling along Cancer Progression Providing a Novel Opportunity for Cancer Diagnosis and Treatment
Kena Song, Zhangqing Yu, Xiangyang Zu, Guoqiang Li, Zhigang Hu, Yun Xue
International Journal of Molecular Sciences.2022; 23(18): 10509. CrossRef
Fibrolamellar carcinoma: An entity all its own
Allison F. O'Neill, Alanna J. Church, Antonio R. Perez-Atayde, Raja Shaikh, Karen J. Marcus, Khashayar Vakili
Current Problems in Cancer.2021; 45(4): 100770. CrossRef
Severe digital ischemia coexists with thrombocytopenia in malignancy-associated antiphospholipid syndrome: A case report and review of literature
Jia-Lei Chen, Xi Yu, Rong Luo, Ming Liu
World Journal of Clinical Cases.2021; 9(36): 11457. CrossRef
Antineoplastics/sodium-benzoate

Reactions Weekly.2020; 1825(1): 46. CrossRef

6,659 View
188 Download
9 Web of Science
11 Crossref

First
Prev
Page of 1
Next
Last

Search